Impact Biomedical (IBO) Interest Coverage Ratio (2022 - 2026)
Impact Biomedical's (IBO) quarterly Interest Coverage Ratio came in at 10.48 in Q2 2026, down 136.27% on a YoY basis from 28.89 in Q2 2025, and up 69.33% quarter-over-quarter from 34.16 in Q1 2026.
Powered by 
Analysis
Impact Biomedical (IBO) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported Interest Coverage Ratio for 5 consecutive years, with 10.48 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio fell 136.27% year-over-year to 10.48; the trailing twelve-month figure through Jun 2026 stood at 7.76 (up 70.92% YoY), and the FY2024 full-year result was 27.0, down 197.6% from the prior year.
- Interest Coverage Ratio rose to 10.48 in Q2 2026 per IBO's latest filing, from 34.16 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2.4 in Q2 2024 and bottomed at 97.15 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 14.05 across 5 years, with a median of 8.32 in 2023.
- The widest YoY moves for Interest Coverage Ratio: up 72.4% in 2024, down 966.2% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 10.42 in 2022, then increased by 12.59% to 9.11 in 2023, then slumped by 966.2% to 97.15 in 2024, then soared by 96.28% to 3.62 in 2025, then slumped by 189.57% to 10.48 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 10.48, 34.16, and 3.62 for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | -10.48 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.48 |
| Mar 31, 2026 | -34.16 |
| Sep 30, 2025 | -3.62 |
| Jun 30, 2025 | -4.43 |
| Mar 31, 2025 | -3.73 |
| Dec 31, 2024 | -97.15 |
| Sep 30, 2024 | -3.70 |
| Jun 30, 2024 | -2.40 |
| Mar 31, 2024 | -3.35 |
| Dec 31, 2023 | -9.11 |
| Sep 30, 2023 | -10.57 |
| Jun 30, 2023 | -8.69 |
| Mar 31, 2023 | -7.95 |
| Dec 31, 2022 | -10.42 |
| Sep 30, 2022 | -9.66 |
| Jun 30, 2022 | -5.40 |